Ttbio Corp. (TPEX:6493)
Taiwan · Delayed Price · Currency is TWD 30.40
+0.10 (0.33%)
Apr 29, 2026, 1:45 PM CST
Ttbio Revenue
In the year 2025, Ttbio had annual revenue of 398.88M TWD with 27.80% growth. Ttbio had revenue of 185.96M in the half year ending December 31, 2025, with 22.48% growth.
Revenue
398.88M
Revenue Growth
+27.80%
P/S Ratio
2.28
Revenue / Employee
2.89M
Employees
118
Market Cap
910.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 398.88M | 86.76M | 27.80% |
| Dec 31, 2024 | 312.12M | -5.97M | -1.88% |
| Dec 31, 2023 | 318.09M | -100.79M | -24.06% |
| Dec 31, 2022 | 418.88M | 113.37M | 37.11% |
| Dec 31, 2021 | 305.52M | 126.56M | 70.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BenQ Medical Technology | 5.25B |
| Nang Kuang Pharmaceutical | 2.16B |
| Bionime | 1.84B |
| Chi Sheng Pharma & Biotech | 1.38B |
| ICARES Medicus | 1.13B |
| Concord Medical | 964.35M |
| Crystalvue Medical | 949.05M |
| Maxigen Biotech | 811.56M |